安科生物：目前公司在研产品的临床试验正在积极推进中

Core Viewpoint - The company Anke Bio (300009) is actively advancing its clinical trials for various innovative drugs, indicating a stable operational status and no undisclosed risks [1] Group 1: Clinical Trials Progress - The clinical trials for the company's in-development products are progressing well, with "HuA21 injection" having completed the enrollment of participants for its Ib/II phase and planning to initiate III phase trials based on interim analysis results [1] - "AK2024 injection," targeting HER2, is currently in I phase clinical trials, showing significant synergistic effects in inhibiting HER2-positive tumor cell proliferation compared to other treatments [1] - "HK010 injection," a dual antibody drug, has completed the enrollment of its first participant in II phase clinical trials [1] Group 2: Additional Projects and Collaborations - "AK2017 injection," a recombinant human growth hormone-Fc fusion protein, is progressing smoothly in III phase clinical trials [1] - The "AK1012 project," aimed at treating respiratory syncytial virus-induced lower respiratory infections in children, has completed I phase trials and is now in II/III phase trials [1] - The company's affiliate, Boshengji, has its PA3-17 injection included in breakthrough therapy designation and is entering critical II phase clinical trials, aiming to complete patient enrollment within a year [1] - Yuan Song Bio, another affiliate, has received IND approval for its lead product "recombinant L-IFN adenovirus injection," which is currently in IIa phase clinical trials in China [1] - The company is collaborating with Afana to develop AFN0328 injection for treating HPV16/18 precancerous lesions, with I phase clinical trials showing very promising data [1]